生物标志物驱动的预后模型预测慢性心衰发病与死亡:EMPEROR-Reduced试验
本研究基于EMPEROR-Reduced试验3730例HFrEF患者,随访中位16个月,开发并外部验证了结合NT-proBNP、hs-cTnT及少量临床变量的预后模型,用于预测心衰住院或心血管死亡复合终点及全因/心血管死亡,模型区分度良好且恩格列净在各风险层均获益。
要点
- NT-proBNP和hs-cTnT是HFrEF患者首要预后预测因子。
- 8变量模型预测主要复合终点c-statistic=0.73。
- 恩格列净在主要终点各风险水平均带来获益。
核心结论
- NT-proBNP与hs-cTnT联合少量常规临床变量可为HFrEF患者提供预后评估,工具易于临床常规使用。
研究设计与样本
- 基于EMPEROR-Reduced试验的预后模型开发与外部验证研究,纳入3730例慢性HFrEF患者,中位随访16个月。
主要发现
- 823例(22%)发生主要复合终点,515例(14%)死亡,其中心血管死亡389例(10%)。
- 主要终点模型含8个变量(NT-proBNP、hs-cTnT、距上次心衰住院时间更短、距心衰诊断时间更长、收缩压更低、NYHA III或IV级、心率更高、外周水肿),均P<0.001,c-statistic=0.73。
- 主要终点最高风险10%患者的事件率是 lowest 10%的>9倍。
- 死亡模型含4个变量(NT-proBNP、hs-cTnT、NYHA III或IV级、缺血性病因),均P<0.001,全因与心血管死亡c-statistic均为0.69。
- 模型在BIOSTAT-CHF研究中外部验证获得相似c-statistic。
临床怎么用
- 可采用NT-proBNP、hs-cTnT联合少量常规临床变量对HFrEF患者进行风险分层。
- 恩格列净在主要终点各风险水平均显示获益,高风险患者亦可使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to generate a biomarker-driven prognostic tool for patients with chronic HFrEF. Circulating levels of N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) each have a marked positive relationship with adverse outcomes in heart failure with reduced ejection fraction (HFrEF). A risk model incorporating biomarkers and clinical variables has not been validated in contemporary heart failure (HF) trials. METHODS AND RESULTS: In EMPEROR-Reduced, 33 candidate variables were pre-selected. Multivariable Cox regression models were developed using stepwise selection for: (i) the primary composite outcome of HF hospitalization or cardiovascular death, (ii) all-cause death, and (iii) cardiovascular mortality. A total of 3730 patients were followed up for a median of 16 months, 823 (22%) patients had a primary outcome and 515 (14%) patients died, of whom 389 (10%) died from a cardiovascular cause. NT-proBNP and hs-cTnT were the dominant predictors of the primary outcome, and in addition, a shorter time since last HF hospitalization, longer time since HF diagnosis, lower systolic blood pressure, New York Heart Association (NYHA) Class III or IV, higher heart rate and peripheral oedema were key predictors (eight variables in total, all P < 0.001). The primary outcome risk score discriminated well (c-statistic = 0.73), with patients in the top 10th of risk having an event rate >9 times higher than those in the bottom 10th. Empagliflozin benefitted patients across risk levels for the primary outcome. NT-proBNP and hs-cTnT were also the dominant predictors of all-cause and cardiovascular mortality, followed by NYHA Class III or IV and ischaemic aetiology (four variables in total, all P < 0.001). The mortality risk model presented good event discrimination for all-cause and cardiovascular mortality (c-statistic = 0.69 for both). These simple models were externally validated in the BIOSTAT-CHF study, achieving similar c-statistics. CONCLUSIONS: The combination of NT-proBNP and hs-cTnT with a small number of readily available clinical variables provides prognostic assessment for patients with HFrEF. This predictive tool kit can be easily implemented for routine clinical use.
引用
- Pocock SJ, Ferreira JP, Gregson J, et al. Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. Eur Heart J. 2021. PMID: 34423361. doi:10.1093/eurheartj/ehab579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。